Zacks.com featured highlights: Tallgrass Energy GP, Baxter International, AO Smith, Southwestern Energy and Rollins
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:30AM CDT
Zacks.com featured highlights: Tallgrass Energy GP, Baxter International, AO Smith, Southwestern Energy and Rollins
BAX: 48.48 (-0.02), ROL: 28.06 (-0.13), SWN: 13.77 (-0.07), AOS: 92.45 (-0.35), TEGP: 22.59 (-0.23)
After Yesterday's Rally of 1.47% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 01, 2:01PM CDT
Baxter International (NYSE:BAX) traded in a range yesterday that spanned from a low of $47.99 to a high of $48.73. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $48.50 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BAX: 48.48 (-0.02)
Buy These 5 Efficient Stocks for Big Upside Potential
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 7:41AM CDT
A portfolio that has been built up by investing in efficient companies may prove to be profitable irrespective of market conditions.
BAX: 48.48 (-0.02), ROL: 28.06 (-0.13), SWN: 13.77 (-0.07), TEGP: 22.59 (-0.23), AOS: 92.45 (-0.35)
Boston Scientific (BSX) Meets Q2 Earnings Estimate, Views Up
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 2:03PM CDT
Boston Scientific Corporation (BSX) announced adjusted EPS of 27 cents in the second quarter of 2016, up 22.7% from the year-ago quarter.
BSX: 24.17 (-0.26), GWPH: 94.07 (-2.04), BAX: 48.48 (-0.02), VASC: 45.35 (-1.10)
Zimmer Biomet (ZBH) Tops Q2 Earnings, Raises FY16 Guidance
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 1:57PM CDT
Zimmer Biomet Holdings, Inc. (ZBH) reported second-quarter 2016 adjusted earnings per share (EPS) of $2.02, up 27.8% year over year.
ZBH: 130.59 (-0.47), GWPH: 94.07 (-2.04), BAX: 48.48 (-0.02), VASC: 45.35 (-1.10)
Baxter's DoseEdge Pharmacy System Identifies Potential Medication Errors for Clinicians Prior to Patient Administration
BusinessWire - Thu Jul 28, 8:00AM CDT
--DoseEdge helps pharmacists and pharmacy technicians correctly and efficiently prepare medication doses
BAX: 48.48 (-0.02)
Global Market for Regenerative Medicine & Stem Cells - What's hot, what's not, what's next by 2019?
GlobeNewswire - Wed Jul 27, 8:30AM CDT
The competitive landscape of the global regenerative medicine market includes players such as CONMED Corporation, Anika Therapeutics Inc., Arthrex, Inc., Baxter International Inc., Smith & Nephew PLC, DePuySynthes Inc., Stryker Corporation, Medtronic Inc., and Zimmer Holdings Inc. Though North America and Europe were the largest markets for regenerative medicines, the market players are increasingly shifting their focus on the emerging economies across Asia Pacific such as India, South Korea, Japan, and China. These countries are registering an increased demand for various bone and joint reconstructive products such as Osteocel Plus (NuVasive Inc.), Trinity Evolution (Orthofix Inc.), and INFUSE Bone Graft (Medtronic Inc.) owing to the rapid growth of the healthcare sector and the rising pool of patients. The market players are investing in rigorous research and development initiatives for innovative products.
SNN: 33.48 (+0.30), MDT: 87.64 (-0.42), BAX: 48.48 (-0.02), ANIK: 49.00 (-1.64), NUVA: 62.63 (-0.66), SYK: 115.70 (-1.32)
Baxter Presents New Evidence Demonstrating REVACLEAR Dialyzer Associated with Lower Drug Use During Hemodialysis
BusinessWire - Wed Jul 27, 7:30AM CDT
--Data have clinical and cost implications given that more than 60 million hemodialysis sessions are completed in the U.S. every year(1)
BAX: 48.48 (-0.02)
Future of Global Pharmacy Automation Systems Market Lies in Automated Medication Dispensing Systems, Finds TMR
PR Newswire Europe - Fri Jul 15, 8:30AM CDT
ALBANY, New York, July 15, 2016 /PRNewswire/ --
ABC: 89.43 (+3.89), MCK: 193.53 (+1.44), BAX: 48.48 (-0.02), OMCL: 37.93 (-0.83), CERN: 61.95 (-0.27)
Ligand to Report Second Quarter Results on August 4th
BusinessWire - Thu Jul 14, 8:00AM CDT
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2016 financial results on August 4, 2016. Ligand's CEO John Higgins, President and COO Matt Foehr and CFO Matt Korenberg will host the conference call.
BAX: 48.48 (-0.02), MRK: 58.33 (-0.33), LGND: 132.68 (-5.85), AMGN: 174.15 (-0.01), NVS: 82.96 (-0.11)
Next Resistance Level for Baxter International (BAX) is $47.00
Comtex SmarTrend(R) - Mon Jul 11, 8:44AM CDT
Shares of Baxter International (NYSE:BAX) have bullishly opened above the pivot of $46.50 today and have reached the first resistance level of $46.82. Investors may be interested in a cross of the next upside pivot targets of $47.00 and $47.50.
BAX: 48.48 (-0.02)
Baxter International, Fluor, BlackRock, Legg Mason and Invesco highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 8:30AM CDT
Baxter International, Fluor, BlackRock, Legg Mason and Invesco highlighted as Zacks Bull and Bear of the Day
BLK: 367.08 (-1.24), BAX: 48.48 (-0.02), IVZ: 28.27 (-0.77), FLR: 52.84 (-0.20), LM: 33.20 (-0.68)
Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 24.17 (-0.26), BAX: 48.48 (-0.02), LMAT: 17.39 (-0.50), GHDX: 29.05 (-1.29)
FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:31AM CDT
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, the FDA go-ahead will expand Medtronic's (MDT) footprint in the billion-dollar neurosurgical market.
ICUI: 116.02 (-1.05), MDT: 87.64 (-0.42), BAX: 48.48 (-0.02), LMAT: 17.39 (-0.50)
Bull of the Day: Baxter International (BAX)
Jeremy Mullin - Zacks Investment Research - Fri Jun 24, 6:00AM CDT
Bull of the Day: Baxter International (BAX)
BAX: 48.48 (-0.02)
GNC Gains as Buyout Rumors of Vitamin Shoppe Resurface
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:32AM CDT
The Vitamin Shoppe buyout rumor first buzzed in immediately after GNC Holdings Inc.'s (GNC) earnings call in the last quarter.
BSX: 24.17 (-0.26), HLF: 66.79 (-1.19), BAX: 48.48 (-0.02), GNC: 19.54 (-0.43)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 116.02 (-1.05), BAX: 48.48 (-0.02), LMAT: 17.39 (-0.50), HOLX: 39.03 (+0.05)
Stryker (SYK) Hits 52-Week High on Positive FY16 View
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:14AM CDT
Share price of Stryker Corp (SYK) rallied to a new 52-week high of $116.99 on Jun 20.
MASI: 52.54 (-0.39), BAX: 48.48 (-0.02), CRY: 14.25 (-0.07), SYK: 115.70 (-1.32)